# AbbVie: Phase 1 study completed, 36 enrolled (Healthy Volunteer)

**Score:** 50/100

| Field | Value |
|---|---|
| Sponsor | AbbVie |
| Sponsor type | Industry (pharma, biotech, medtech) |
| Study | A Study to Assess the Adverse Events and How Oral ABBV-1042 Moves Through the Body of Healthy Adult Participants |
| NCT ID | NCT07222709 |
| Phase | Phase 1 |
| Status | completed |
| Conditions | Healthy Volunteer |
| Intervention types | drug |
| Target enrollment | 36 |
| Site countries | United States |
| Posted | 2025-10-30 |
| Planned start | 2025-10-27 |
| Event | Completed |
| Event date | 2026-09-18 |
| Last update posted | 2026-10-15 |

## Why this score
- Industry sponsor (buys outsourced services).
- Completed: closeout, analysis and the next study ahead.

Source: ClinicalTrials.gov (U.S. National Library of Medicine) API v2 (https://clinicaltrials.gov/study/NCT07222709). Last refreshed: 2026-11-05T08:46:16.625Z.
From public ClinicalTrials.gov registrations. Sponsor and study level only: we never list investigators, contacts or participants. A registration describes a planned study and can change. Status changes are read from each study's current status, actual dates and latest posted update, not a full change history, so an update can be a correction rather than a new change. Verify on ClinicalTrials.gov.